Sanofi Consumer Healthcare India Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 11 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹10.2K Cr
Focus is on growth and penetration in India, aiming to increase volumes and market reach. No forward-looking assumptions or specific aspirational growth guidance on earnings or profits were given by Sanofi Consumer Healthcare India Limited.
From Sanofi Consumer Healthcare India Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹4,222
Market Cap
₹10.2K Cr
P/E Ratio
38.5
Revenue Rank
Margin Rank
How does Sanofi Consumer Healthcare India Ltd rank in Pharmaceuticals & Biotechnology?
Compare Sanofi Consumer Healthcare India Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Sanofi Consumer Healthcare India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹229 Cr, net profit ₹68 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →Focus is on growth and penetration in India, aiming to increase volumes and market reach.
- →Sustainable, profitable growth is the agenda, balancing top line, market share, and bottom line.
- →Innovation and new product launches (e.g., Allegra D) are key pillars for future growth.
- →Significant investment has begun since Q2 2025 into brand building, digital engagement, and expanding consumer reach.
- →Expansion plans include increasing healthcare professional (HCP) reach, especially in underpenetrated regions like the East.
- →The sales force of ~350 medical reps is expected to improve productivity and possibly expand depending on business case analysis.
- →Inorganic growth opportunities are being explored cautiously with global support.
- →Expect growth faster than the category and competitors, with plans to double HCP coverage within 2026.
- →Sales are recovering post-recalls, with some brands nearly back to pre-recall run rates.
📈 Profitability & Margins
Rank 3- →No forward-looking assumptions or specific aspirational growth guidance on earnings or profits were given by Sanofi Consumer Healthcare India Limited. (Page 15)
- →The leadership emphasizes sustainable, profitable growth as a key agenda, aiming for growth alongside profitability. (Pages 18-19)
- →Operating profit increased by 13% and PAT grew by 33% in 2025, reflecting recent performance. (Page 6)
- →Growing faster than the market and increasing market share are key performance metrics tied to evaluation. (Page 21)
- →Investments in brand building and digital initiatives have started and are expected to contribute to growth going forward. (Pages 14-15)
- →No specific EPS guidance or quantified future profit projections were shared during the discussion. (Page 15)
🏗️ Capital Expenditure Plans
Yes- →Sanofi Consumer Healthcare India Limited is focused on smart and disciplined capital spending.
- →Investments are targeted in the right places with high focus, avoiding indiscriminate spending.
- →Performance analytics teams work on optimizing productivity and efficiency, especially in the sales force.
- →The company is evaluating different reach models including digital and Omni-channel approaches before deciding on expanding the sales force.
- →There is a clear intent on sustainable, profitable growth with increased investments in brand building and digital marketing started since Q2 of the previous year, which will continue.
- →The organization benefits from strong local manufacturing capabilities, reducing dependency on global supplies, thus controlling capital deployment in supply chain.
- →Discussions on inorganic opportunities exist but require further clarity on strategic fit and investment cases.
- →Overall, the capex/investment approach is cautious and focused on driving growth efficiently rather than broad or aggressive expansion.
💰 Fundraising & Capital Structure
No information- →There is no mention of any current or future fundraising plans through debt or equity in the transcript.
- →Sanofi Consumer Healthcare India Limited did not provide any forward-looking statements regarding fundraises, as stated by Mr. Richard D’Souza (CFO) on page 15.
- →The company is focused on growth through brand investment, innovation, and improving productivity rather than external fundraising.
- →Discussions around inorganic growth or acquisitions are ongoing but no specific fundraising plans were disclosed (page 19).
- →Overall, the emphasis is on sustainable, profitable growth funded through operational performance rather than by raising new capital.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Sanofi Consumer Healthcare India Ltd Q3 FY26 results?
Focus is on growth and penetration in India, aiming to increase volumes and market reach. No forward-looking assumptions or specific aspirational growth guidance on earnings or profits were given by Sanofi Consumer Healthcare India Limited.
What is Sanofi Consumer Healthcare India Ltd share price analysis?
Sanofi Consumer Healthcare India Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 38.5 with a market cap of ₹10,237 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sanofi Consumer Healthcare India Ltd planning capital expenditure?
Sanofi Consumer Healthcare India Limited is focused on smart and disciplined capital spending.
Keep Sanofi Consumer Healthcare India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.